Sustiva Articles
Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx
6 May 2013
Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per share
29 January 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
Blockbuster status predicted for co-formulation of rilpivirine and Truvada with sales of over $2 billion in the HIV Drug Market by 2018
7 January 2010
Bristol-Myers sees 64% leap in 3rd quarter 2009 ongoing earnings
23 October 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
FDA panel OKs Pfizer’s Selzentry for broader us in HIV naive patients, but drug criticized for its cost
12 October 2009
EU approves expanded use of Merck & Co’s Isentress in adult patients with HIV-1 Infection
16 September 2009
Mylan's Matrix gets tentative FDA approval under PEPFAR for generic Atripla HIV Treatment
19 August 2009
Gilead files 2nd patent suit against Teva
15 May 2009
B-MS' 1st qtr hit by tax and legal costs
29 April 2009
Profit up 22% at Gilead on pipeline strength
27 April 2009
Teva files ANDA on Gilead
7 April 2009
Tibotec fully enrolled for HIV trial
30 March 2009
Thailand "threat" to USA over CL policy
16 March 2009
Thailand group fights EU-ASEAN FTA
2 March 2009
Merck & Co's drug cuts HIV across sub-groups
16 February 2009
Stock Commentary - New York week to Feb 2, 2009
9 February 2009
Tibotec recruiting for two Ph III trials of NNRTI
12 January 2009
Isentress cuts viral load in untreated patients
3 November 2008
Bristol-Myers Squibb's 3rd-qtr 2008 profit triples due to big gain from $4.1B sales of ConvaTec
3 November 2008
Gilead up almost 30% on HIV franchise
27 October 2008
Thailand's new Health Minister will keep CLs
6 October 2008
Thailand's HIV/AIDS drug resistance problem
29 September 2008
Brazil OKs copy of Merck's Stocrin
29 September 2008
Stock Commentary - New York week to Sept 8, 2008
15 September 2008
76% of TMC278 patients achieve undetectable HIV
18 August 2008
Isentress works well in untreated HIV patients
18 August 2008
Gilead leads in selling Atripla in new countries
11 August 2008
B-MS' profit accelerates on good exchange rate
4 August 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
South Africa DoH's $468M tender for ARVs
14 July 2008
South Africa to drop case against Merck & Co
9 June 2008
B-MS restructure cuts into 1st-qtr profit
5 May 2008
Gilead record sales push revenue up 22%
28 April 2008
India NGOs at war with cancer drug patents
7 April 2008
Thailand's GPO: CVD and ARV copycats plan
31 March 2008
Selzentry triples number of patients at undetectable HIV
18 February 2008
Plavix rebound cuts B-MS' 4th-qtr 2007 loss and offsets $797M charge
11 February 2008
Stock Commentary - New York week to Jan 28, 2008
4 February 2008
Brazil's pipeline patents under threat
28 January 2008
EC approves B-MS/Gilead's Atripla
24 December 2007
HIV/AIDS drug Atripla debuts in UK
24 December 2007
Cipla ARV price cut does not appease campaigners
24 December 2007
Harvard study finds Brazil saved $1B on ARVs
26 November 2007
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
Less side effects with switch from Combivir to Truvada
5 November 2007
CHMP recommends approval of Atripla for HIV-1
29 October 2007
Gilead's 3rd-qtr 2007 revenue jumps 41%
29 October 2007
Atripla approved in Canada for HIV-1
22 October 2007
AHF blames drug firms for slow ARV uptake
24 September 2007
India's Cipla pricing claims disputed
3 September 2007
India's regulators investigate Cipla pricing claims
3 September 2007
Boeh Ing's Viramune may cut CV risk
6 August 2007
Pfizer's maraviroc fares well vs efavirenz
6 August 2007
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
6 August 2007
Stock Commentary - New York week to July 23, 2007
30 July 2007
Thailand's GPO to be overhauled
30 July 2007
Canadian regulators clear 300mg Reyataz
28 May 2007
Thailand "may revoke" compulsory licence
28 May 2007
Brazil's Stocrin move will force down prices
21 May 2007
Brazil in new patent grab threat
30 April 2007
Stock Commentary - New York week to April 23, 2007
30 April 2007
Gilead's 1st-qtr 2007 net income sky-rockets 55%
30 April 2007
Thailand's rulers extend "war" on patents
26 February 2007
Merck & Co cuts AIDS drug prices to LDCs
26 February 2007
Gilead's share price up on strong 4th-qtr sales
12 February 2007
Thailand's "patent busting" goes ahead
7 February 2007
Boeh Ingel posts strong long-term data on Viramune
5 February 2007
Gilead subpoenaed over HIV drugs
18 December 2006
Thailand initiates compulsory licensing
11 December 2006
World AIDS Day progress report on cure and recrimination on drug resistant HIV/AIDS
11 December 2006
Gilead's 3rd-qtr losses hit $52M on Corus buy
30 October 2006
Stock Commentary - New York week to Oct 16, 2006
23 October 2006
HIV drug Atripla submitted to EMEA
16 October 2006
B-MS and Gilead Sci sign Atripla accord
9 October 2006
NRTI-sparing approach highlighted by new data
28 August 2006
Stock Commentary - New York week to July 24, 2006
24 July 2006
Atripla approved by FDA for use in HIV-1 therapy
17 July 2006
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
